RECENT FUNDING
  1. Recent Funding
  2. Investors
  3. TCG Crossover
T

TCG Crossover portfolio

TCG Crossover has 8 portfolio companies on record at Recent Funding, with 4 investments in the last 12 months.

Type: Crossover fund.
Portfolio on Recent Funding: 8.
Deals, last 12 months: 4.
Rounds led: 5 of 8.
Capital in their rounds: $1.17B.
Latest deal: Soufflé Therapeutics · Oct 13, 2026.
About this page

It is a crossover fund based in Palo Alto, US, founded in 2021. It led 5 of the 8 rounds it joined. Its most recent investment on record is Soufflé Therapeutics's $135M Series B+ round in October 2026, alongside TAS Partners, Leaps by Bayer, Vida Ventures and 6 others. By category, its portfolio leans toward Health and bio (8) and Data and analytics (1). It has co-invested with Temasek, Invus and Janus Henderson Investors, most often Temasek (3 rounds).

About TCG Crossover

Firm type: Crossover fund.
Headquarters: Palo Alto, US.
Founded: 2021.
Stages: Seed, Series A, Series B, Series C, Growth, Late Stage.
Sectors: Biotech, Healthtech.
Portfolio companies: 27.
Exits: 1.
Rounds led: 1.

Fund returns

FundVintageSizeNet IRRTVPIDPIAs of
TCG Crossover Fund2021—16.4%1.42x0.71xNov 30, 2025

What TCG Crossover invests in

TCG Crossover recent investments

How TCG Crossover invests

StageDealsCapital in rounds
Series B+ 7 88%$1.08B
round 1 13%$94M
YearDealsCapital in rounds
2021 2 25%$323M
2024 1 13%$105M
2025 1 13%$74M
2026 4 50%$668M

TCG Crossover portfolio companies

CompanyRound with TCG CrossoverTotal raisedLatest raise
SSoufflé Therapeutics
Health and bio
Series B+ · $135M$335MOct 13, 2026
Series B+
TTriGemX Bio
Health and bio
round · $94M · lead$94MOct 1, 2026
round
VVaderis Therapeutics
Health and bio
Series B+ · $152M · lead$152MAug 11, 2026
Series B+
CCorxel
Health and bio
Series B+ · $287M$287MJan 26, 2026
Series B+
AArbor Biotechnologies
Health and bio
Series B+ · $74M · lead$289MMar 18, 2025
Series B+
PPathalys
Health and bio
Series B+ · $105M · lead$255MAug 20, 2024
Series B+
SSynthekine
Health and bio
Series B+ · $108M$290MJan 6, 2023
Series B+
MMirador Therapeutics
Health and bio
backer$650MJan 13, 2026
Series B+

Most frequent co-investors

Similar investors

Investors whose portfolios on Recent Funding center on the same category (Health and bio).

How this is counted

Net returns as reported by the public-pension and foundation LPs invested in each fund.

Firm profile and fund returns: Fundraising Fox Open Dataset v2026-11, CC BY 4.0. Track-record counts are theirs, not Recent Funding's.

Share is of the 8 rounds on Recent Funding that name TCG Crossover. Rounds with no announced date are left out of the year split, and "round" is a round whose stage is not on file.

Portfolio companies are the companies on Recent Funding with a round that lists TCG Crossover, which is a subset of its real portfolio. API: /api/v1/investors/tcg-crossover (get a free API key). More: the most active VC firms and new venture capital funds.

Top raises, every week

The week's top funded startups and market insights, in your inbox every Monday.

Unsubscribe anytime · privacy